American Kidney Fund’s Kidney Kitchen™ Wins 2019 Gold MarCom Award
05 déc. 2019 09h30 HE
|
American Kidney Fund
ROCKVILLE, Md., Dec. 05, 2019 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF)’s online Kidney Kitchen™ has won a Gold 2019 MarCom Award in the Digital Media – Website – Nonprofit category. ...
DSG Global Inc. Announces a Major Strategic Partnership in China to Integrate TAG Systems with Electric Vehicles Incorporating the Company’s Advanced Fleet Management Capabilities
02 oct. 2019 09h00 HE
|
DSG Global Inc.
The Company has exclusive rights to market Jonway Group’s electric vehicles for resale in the United States, Canada, Mexico and the Caribbean Surrey, British Columbia, Oct. 02, 2019 (GLOBE...
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
26 sept. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
20 sept. 2019 03h05 HE
|
FibroGen, Inc; Astellas Pharma Inc.
SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji...
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
06 sept. 2019 09h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth...
DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
03 sept. 2019 16h15 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor...
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 16h35 HE
|
DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II...
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
12 août 2019 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference,...
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
08 août 2019 16h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on...
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
19 juin 2019 16h04 HE
|
DiaMedica Therapeutics Inc.
Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney...